source
- Longeveron’s pediatric heart stem-cell trial misses primary endpoint, prompting cost cutsLongeveron reported that its phase 2b Elpis II trial of the stem-cell product laromestrocel in infants with hypoplastic left heart syndrome failed to meet its primary efficacy endpoint. The study…
- Kennedy appoints eight specialists to U.S. Preventive Services Task Force, ending year-long vacancyHealth secretary Robert F. Kennedy Jr. appointed eight new members to the U.S. Preventive Services Task Force, filling vacancies after the panel had not met for more than a year. The appointees in…